Breaking News, Financial News

Gilead 1Q Sales Slip 4% Due to Lower Veklury Sales

Biktarvy sales up 24% and Oncology revenue increased 59% in the quarter, driven by Trodelvy and Cell Therapy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead 1Q Revenue: $6.4 billion (-4%) 1Q Earnings: $985 million (earnings were $12 million 1Q22) Comments: Results in the quarter were impacted by lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and Oncology. HIV product sales increased 13% to $4.2 billion in the quarter. Biktarvy sales increased 24% mostly reflecting higher demand. Descovy sales increased 20% primarily driven by higher demand and favorable pricing dynamics. Liver Disease portfolio sales, which in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters